Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction.

Autor: Peters AE; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Clare RM; Duke Clinical Research Institute, Durham, NC, USA., Chiswell K; Duke Clinical Research Institute, Durham, NC, USA., Harrington J; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Kelsey A; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Hernandez A; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Felker GM; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Mentz RJ; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., DeVore AD; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA.
Jazyk: angličtina
Zdroj: ESC heart failure [ESC Heart Fail] 2024 Oct; Vol. 11 (5), pp. 2813-2824. Date of Electronic Publication: 2024 May 16.
DOI: 10.1002/ehf2.14777
Abstrakt: Aims: Clinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the generalizability of trial findings.
Methods and Results: Patients with HFmrEF/HFpEF from a large US healthcare system were identified through a computable phenotype applied in linked imaging and electronic health record databases. We evaluated shared eligibility criteria from five recent/ongoing HFmrEF/HFpEF trials (PARAGON-HF, EMPEROR-Preserved, DELIVER, FINE-ARTS, and SPIRRIT-HFpEF) and compared clinical and echocardiographic features as well as outcomes between trial-eligible and trial-ineligible patients. Among 5552 patients with HFpEF/HFmrEF, 792 (14%) were eligible for trial consideration, having met all criteria assessed. Causes of ineligibility included lack of recent loop diuretics (37%), significant pulmonary disease (24%), reduced estimated glomerular filtration rate (17%), recent stroke/transient ischaemic attack (13%), or low natriuretic peptides (12%); 53% of ineligible patients had >1 reason for exclusion. Compared with eligible patients, ineligible patients were younger (age 71 vs. 75 years, P < 0.001) with higher rates of coronary artery disease (66% vs. 59%, P < 0.001) and peripheral vascular disease (40% vs. 33%, P < 0.001), but less mitral regurgitation, lower E/e' ratio, and smaller left atrial sizes. Both eligible and ineligible patients demonstrated high rates of structural heart disease consistent with HFpEF [elevated left atrial size or left ventricular (LV) hypertrophy/increased LV mass], although this was slightly higher among eligible patients (95% vs. 92%, P = 0.001). The two cohorts demonstrated similar LV global longitudinal strain along with a similar prevalence of atrial fibrillation/flutter, hypertension, and obesity. Ineligible patients had similar all-cause mortality (33% vs. 33% at 3 years) to those eligible but lower rates of heart failure hospitalization (20% vs. 28% at 3 years, P < 0.001).
Conclusions: Among patients with HFmrEF/HFpEF from a large health system, approximately one in seven were eligible for major trials based on key criteria applied through a clinical computable phenotype. These findings highlight the large proportion of patients with HFmrEF/HFpEF ineligible for contemporary trials for whom the generalizability of trial findings may be questioned and further investigation would be beneficial.
(© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz: